Anika Therapeutics (ANIK)Director bought ~$73K

~$73K

Approx. value · 5,000 sh @ $14.66

55K

Holds after · shares reported

Traded

May 1, 2026

Filed

May 4, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Apr 24, 2026Company filing · Form 8-K · Results, Executive changeChanged a top executive or board member, and reported its results“On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the “Board”) of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”).”
2. Apr 30, 2026Insider · Largest insider buy since 2006CEO purchased ~$150K of ANIK shares in the open market
3. May 1, 2026 · this disclosureInsider · First buy since 2021Director purchased ~$73K of ANIK shares in the open market

What came next

1. Jun 18, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On April 26, 2026, the board of directors, or the Board, of Anika Therapeutics, Inc., or the Company, adopted and approved, subject to stockholder approval, a sixth amendment and restatement of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan as previously amended, or the 2017 Plan, and on June 8, 2026, the Board adopted and approved, subject to stockholder approval, a revised sixth amendment and restatement…”
2. Jul 10, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
3. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
4. Aug 3, 2026Insider · Their first buy on recordDirector purchased ~$21K of ANIK shares in the open market
5. Aug 4, 2026InsiderDirector purchased ~$20K of ANIK shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Anika Therapeutics

For Anika Therapeutics, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANIK page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Anika Therapeutics

• SEC Form 4Aug 5, 2026
• SEC Form 4Aug 5, 2026
• SEC Form 4Apr 30, 2026
• House Clerk periodic transaction reportAug 26, 2021
• House Clerk periodic transaction reportAug 26, 2021
• House Clerk periodic transaction reportAug 26, 2021

Everything OQRO holds on this company is on its ANIK page.